Total Funding
38
31
Total FundingGrant raised
Growth Score
-3 pts
Heat Score
-21 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Events
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
242675
Thelial Technologies engages in targeted carcinoma drug discovery and development.
Richard Hampson: CEO & Founder- Pedro Vilarinho: Business AdvisorPast Role: Biomode, CEO
About the Company
Thelial is a targeted carcinoma drug discovery and development company.
theLiTE™ (Thelial – Live Targeted Epithelia) is our proprietary targeted carcinoma drug discovery platform technology; screening a library of more than 1200 drug candidates we have discovered six carcinoma targeted drug candidates, validating theLiTE™.
To prove the
concept we combine theLiTE™ with a powerful approach to advance novel therapies: drug repositioning, identifying new roles for known drug compounds.
In parallel we develop a novel treatment class, targeting actin in cancer.
